Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
This dual dysfunction of microglia and astrocytes leads to extensive oxidative stress, immune activation, and eventual neuronal degradation
Free from major allergens, vegan, and Non-GMO
The additional GIP pathway engagement may also support improved blood sugar control and reduced cardiovascular risk markers
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
NRF2 regulation processes as a source of potential drug targets against neurodegenerative diseases
US$ 27.48
US$ 26.16
US$ 25.09
US$ 27.58
US$ 28.99
US$ 29.40
US$ 24.32
US$ 29.34
US$ 22.44
US$ 21.82
.webp)
US$ 23.23
US$ 20.60
US$ 28.19
